GlassScriptPhysician profile
Kalpana Patel
NPI 1285641233
$10,961.92
in general payments reported to CMS, 2019-2025
41 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,075 · 2020: $250 · 2021: $818 · 2022: $1,849 · 2023: $2,121 · 2024: $2,397 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,950 · Education: $21.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,949.58 |
| Education | $21.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,905.63 | 2019-2025 | |
| Janssen Biotech, INC. | $1,401.53 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $986.47 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $660.97 | 2019-2025 | |
| Madrigal Pharmaceuticals | $633.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $548.06 | 2021-2024 | Zeposia |
| Genzyme Corporation | $523.41 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $428.32 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $320.71 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $252.84 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $208.97 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $190.15 | 2019-2024 | Rebyota, Clenpiq |
| Qol Medical, LLC | $164.95 | 2023-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $162.25 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $158.53 | 2023-2025 | Ibsrela |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $137.00 | 2021-2025 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $121.25 | 2022 | |
| Ironwood Pharmaceuticals, INC | $120.98 | 2019-2024 | Linzess |
| Glaxosmithkline, LLC. | $119.92 | 2023 | Shingrix |
| Fresenius Kabi USA, LLC | $113.37 | 2023 | Idacio |
| Organon LLC | $81.04 | 2022-2023 | Hadlima |
| Capsovision, INC. | $80.79 | 2025 | Capsocam Plus |
| Braintree Laboratories, INC. | $74.37 | 2019-2024 | Sutab, Suflave |
| Celltrion USA INC. | $73.54 | 2024-2025 | Vegzelma, Zymfentra |
| Boston Scientific Corporation | $54.29 | 2022 | |
| Evoke Pharma, INC. | $48.84 | 2022-2023 | Gimoti |
| Ethicon US, LLC | $38.57 | 2019 | |
| Shield Therapeutics INC | $38.25 | 2024 | |
| Lilly USA, LLC | $36.97 | 2024-2025 | Omvoh |
| Conmed Corporation | $34.69 | 2025 | Conmed Hemostasis, Conmed Dilation |
| Daiichi Sankyo INC. | $34.07 | 2019-2021 | |
| Amgen INC. | $31.94 | 2020 | |
| Sandoz INC. | $25.23 | 2023 | Hyrimoz |
| Albireo Pharma, INC. | $23.52 | 2024 | Iqirvo |
| Nestle Healthcare Nutrition INC. | $22.52 | 2023 | |
| Allergan, INC. | $19.52 | 2019 | |
| Shionogi INC | $19.05 | 2019 | |
| Exact Sciences Corporation | $18.24 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.18 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $16.59 | 2024 | Talicia |
| Medtronic, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalpana Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.